论文部分内容阅读
目的探讨利福布汀联合莫西沙星治疗耐多药结核病(MDR-TB)的临床疗效。方法选取2013年7月—2014年7月峡江县疾病控制中心收治的106例MDR-TB患者,按照治疗方案不同分为莫西沙星组50例和联合组56例。莫西沙星组患者给予莫西沙星治疗,联合组患者给予利福布汀联合莫西沙星治疗,比较两组患者痰菌转阴率、临床疗效以及不良反应发生情况。结果联合组患者痰菌转阴率为91.07%(51/56),高于莫西沙星组的76.00%(38/50),差异有统计学意义(P<0.05);联合组患者总有效率为92.86%,高于莫西沙星组的72.00%,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论利福布汀联合莫西沙星治疗MDR-TB的疗效显著,患者痰菌转阴率高,不良反应少,可作为治疗MDR-TB的优选方案。
Objective To investigate the clinical efficacy of rifabutin combined with moxifloxacin in the treatment of multidrug-resistant tuberculosis (MDR-TB). Methods A total of 106 patients with MDR-TB treated in Xiajiang County Center for Disease Control and Prevention from July 2013 to July 2014 were selected and divided into Moxifloxacin group (n = 50) and combination group (n = 56) according to different treatment regimens. The moxifloxacin group was given moxifloxacin, and the combination group was given rifabutin combined with moxifloxacin. The sputum negative rate, clinical efficacy and adverse reactions of the two groups were compared. Results The rate of sputum negative conversion in the combined group was 91.07% (51/56), which was higher than that in the moxifloxacin group (76.00%, 38/50) (P <0.05). The total effective rate (92.86%), higher than that in moxifloxacin group (72.00%), the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combination of rifabutin and moxifloxacin has a significant effect on the treatment of MDR-TB. The sputum bacterium has a high negative conversion rate and few adverse reactions. It can be used as the optimal treatment for MDR-TB.